Date: 2016-04-12
Type of information: Presentation of results at a congress
phase: preclinical
Announcement: presentation of results at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID
Company: AmpliPhi BioSciences (USA - VA)
Product: AB-PA01 (Pseudomonas aeruginosa bacteriophages)
Action
mechanism: bacteriophage
Disease: Pseudomonas aeruginosa infections in cystic fibrosis patients
Therapeutic area: Infectious diseases - Rare diseases
Country:
Trial details:
Latest
news: * On April 12, 2016, AmpliPhi Biosciences presented data at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) summarizing both the in vitro and in vivo activity of its proprietary, investigational phage mix AB-PA01. The data showed that AB-PA01 was capable of infecting and killing 87.8% of 369 Pseudomonas aeruginosa clinical isolates from a global population of cystic fibrosis patients. AB-PA01 also demonstrated activity against 83.3% of 60 P. aeruginosa global, clinical isolates from non-cystic fibrosis patients. In total, AB-PA01 was shown to be active in vitro against 87.2% of the 429 clinical isolates tested, including both multi-drug resistant (MDR) and sensitive strains of P. aeruginosa. Additionally, in an acute murine lung infection model all AB-PA01 doses administered demonstrated activity similar to meropenem. The ECCMID poster presented by Dr. Morales is titled, “Bacteriophage therapy for the treatment of P. aeruginosa infections in cystic fibrosis patients”.
